Stephanie Paine, APRN
Staff Affiliate - YNHHAbout
Titles
Staff Affiliate - YNHH
Biography
She currently works at the Smilow Cancer Hospital Care Center at Greenwich Hospital in Greenwich, CT. She has worked at the Brain Tumor Center at Smilow Cancer Hospital in New Haven, CT and the Weill Cornell Brain and Spine Center at New York-Presbyterian/Weill Cornell Medical Center in New York, NY. Prior to becoming a nurse practitioner, she worked as a registered nurse at Montefiore Medical Center in the Bronx, NY.
She received both her Bachelor of Science in Nursing and Master of Science in Nursing from Columbia University. She is a board certified Adult-Gerontology Nurse Practitioner through the American Nurses Credentialing Center. She also holds a B.A. from the University of Rochester.
Stephanie is very passionate about patient advocacy through education and strong patient-provider relationships.
Appointments
Departments & Organizations
Education & Training
- MSN
- Columbia University School of Nursing (2013)
- BSN
- Columbia University School of Nursing (2010)
- BA
- University of Rochester School of Arts and Sciences (2009)
Research
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023Recruiting ParticipantsA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting Participants